

SmartPA Criteria Proposal

Drug/Drug Class:	Antiemetics, THC Derivatives PDL Edit
First Implementation Date:	April 4, 2019
Revised Date:	April 7, 2022
Prepared For:	MO HealthNet
Prepared By:	MO HealthNet/Conduent
Criteria Status:	<input checked="" type="checkbox"/> Existing Criteria <input type="checkbox"/> Revision of Existing Criteria <input type="checkbox"/> New Criteria

Executive Summary

Purpose: The MO HealthNet Pharmacy Program will implement a state-specific preferred drug list.

Why Issue Selected: The tetrahydrocannabinol (THC) derivative agents have indications that include prevention and treatment of nausea and vomiting associated with chemotherapy. Dronabinol and Marinol® also have an indication for treating anorexia in patients with AIDS. The management of chemotherapy-induced nausea and vomiting is a critical aspect of treating cancer patients. The THC derivative agents are controlled substances and therefore need to be managed appropriately.

Total program savings for the PDL classes will be regularly reviewed.

Program-Specific Information:	Preferred Agents	Non-Preferred Agents
	<ul style="list-style-type: none"> Dronabinol 	<ul style="list-style-type: none"> Cesamet® Marinol®

Type of Criteria: Increased risk of ADE Preferred Drug List
 Appropriate Indications Clinical Edit

Data Sources: Only Administrative Databases Databases + Prescriber-Supplied

Setting & Population

- Drug class for review: Antiemetics, THC Derivatives
- Age range: All appropriate MO HealthNet participants

Approval Criteria

- Failure to achieve desired therapeutic outcomes with a trial on 1 or more preferred agents
 - Documented trial period for preferred agents (2 claims in past 90 days) **OR**
 - Documented ADE/ADR to preferred agents

Denial Criteria

- Lack of adequate trial on required preferred agents
- Therapy will be denied if all approval criteria are not met

Required Documentation

Laboratory Results:
MedWatch Form:

Progress Notes:
Other:

Disposition of Edit

Denial: Exception "0160" (Preferred Drug List Edit)
Rule Type: PDL

Default Approval Period

1 year

References

- Evidence-Based Medicine and Fiscal Analysis: "Antiemetic Agents – Therapeutic Class Review", Conduent Business Services, L.L.C., Richmond, VA; November 2021.
- Evidence-Based Medicine Analysis: "Antiemetics – 5-HT3, THC Derivatives, NK1 & Other Agents", UMKC-DIC; September 2021.
- USPDI, Micromedex; 2021.
- Drug Facts and Comparisons On-line; 2021.